UroGen Pharma (URGN) Competitors $11.51 +0.10 (+0.88%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.50 0.00 (-0.04%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. MIRM, BHC, BEAM, GMTX, NAMS, VCEL, BLTE, TARS, JANX, and SDGRShould you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Mirum Pharmaceuticals (MIRM), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), Vericel (VCEL), Belite Bio (BLTE), Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical products" industry. UroGen Pharma vs. Mirum Pharmaceuticals Bausch Health Companies Beam Therapeutics Gemini Therapeutics NewAmsterdam Pharma Vericel Belite Bio Tarsus Pharmaceuticals Janux Therapeutics Schrödinger Mirum Pharmaceuticals (NASDAQ:MIRM) and UroGen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations. Does the media favor MIRM or URGN? In the previous week, UroGen Pharma had 20 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 27 mentions for UroGen Pharma and 7 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.53 beat UroGen Pharma's score of 0.61 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive UroGen Pharma 6 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, MIRM or URGN? UroGen Pharma has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$336.89M6.41-$163.41M-$1.85-23.62UroGen Pharma$90.40M5.87-$102.24M-$3.23-3.56 Do analysts recommend MIRM or URGN? Mirum Pharmaceuticals presently has a consensus target price of $58.20, indicating a potential upside of 33.21%. UroGen Pharma has a consensus target price of $32.86, indicating a potential upside of 185.47%. Given UroGen Pharma's higher probable upside, analysts plainly believe UroGen Pharma is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09UroGen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is MIRM or URGN more profitable? Mirum Pharmaceuticals has a net margin of -31.69% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% UroGen Pharma -129.11%N/A -47.94% Do institutionals & insiders have more ownership in MIRM or URGN? 91.3% of UroGen Pharma shares are owned by institutional investors. 22.9% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk and volatility, MIRM or URGN? Mirum Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, UroGen Pharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Does the MarketBeat Community believe in MIRM or URGN? UroGen Pharma received 245 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 75.86% of users gave Mirum Pharmaceuticals an outperform vote while only 74.36% of users gave UroGen Pharma an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13275.86% Underperform Votes4224.14% UroGen PharmaOutperform Votes37774.36% Underperform Votes13025.64% SummaryMirum Pharmaceuticals beats UroGen Pharma on 11 of the 18 factors compared between the two stocks. Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUroGen PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$530.69M$6.85B$5.56B$8.03BDividend YieldN/A2.91%5.07%4.23%P/E Ratio-3.657.5022.7718.87Price / Sales5.87259.06405.67106.84Price / CashN/A65.8538.1834.62Price / Book-4.146.566.794.34Net Income-$102.24M$143.63M$3.22B$248.06M7 Day Performance16.62%3.35%3.36%3.18%1 Month Performance9.31%10.29%6.91%8.28%1 Year Performance-19.51%-3.67%16.16%5.04% UroGen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUroGen Pharma4.2932 of 5 stars$11.51+0.9%$32.86+185.5%-19.3%$530.69M$90.40M-3.65200Analyst ForecastAnalyst RevisionNews CoverageMIRMMirum Pharmaceuticals4.2629 of 5 stars$41.31+1.3%$58.20+40.9%+70.7%$2.04B$336.89M-20.45140Upcoming EarningsPositive NewsBHCBausch Health Companies4.1947 of 5 stars$5.41-0.6%$7.17+32.5%-33.1%$2.00B$9.63B-45.0819,900Analyst UpgradeBEAMBeam Therapeutics3.1272 of 5 stars$19.80+1.4%$49.45+149.8%-10.9%$1.99B$63.52M-11.25510Upcoming EarningsShort Interest ↑News CoverageGMTXGemini TherapeuticsN/A$45.42-1.6%N/A+71.3%$1.97BN/A-45.4230NAMSNewAmsterdam Pharma3.1918 of 5 stars$17.83+1.8%$43.33+143.0%-11.3%$1.96B$45.56M-6.864Positive NewsVCELVericel2.3894 of 5 stars$38.74-2.5%$60.86+57.1%-18.7%$1.94B$237.22M645.77300Upcoming EarningsPositive NewsBLTEBelite Bio2.8721 of 5 stars$60.18+3.3%$96.67+60.6%+52.5%$1.92BN/A-54.2210News CoveragePositive NewsTARSTarsus Pharmaceuticals2.1115 of 5 stars$49.72-0.6%$63.67+28.1%+36.8%$1.91B$182.95M-13.0550Earnings ReportUpcoming EarningsAnalyst ForecastNews CoveragePositive NewsGap DownJANXJanux Therapeutics3.0381 of 5 stars$32.23+3.8%$95.25+195.5%-47.3%$1.90B$10.59M-27.5530Upcoming EarningsInsider TradeNews CoveragePositive NewsSDGRSchrödinger2.5212 of 5 stars$25.75-2.6%$33.00+28.2%+9.1%$1.88B$207.54M-11.00790Upcoming EarningsPositive NewsGap Up Related Companies and Tools Related Companies Mirum Pharmaceuticals Competitors Bausch Health Companies Competitors Beam Therapeutics Competitors Gemini Therapeutics Competitors NewAmsterdam Pharma Competitors Vericel Competitors Belite Bio Competitors Tarsus Pharmaceuticals Competitors Janux Therapeutics Competitors Schrödinger Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy URGN Stock Free URGN Stock Alerts